Literature DB >> 11313690

Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia.

U Platzbecker1, C Thiede, J Freiberg-Richter, C Röllig, A Helwig, U Schäkel, B Mohr, M Schaich, G Ehninger, M Bornhäuser.   

Abstract

Two patients with high-risk acute myeloid leukemia (AML) whose bone marrow aspirates showed more than 25% blasts between 2 and 4 weeks after the first induction chemotherapy immediately received modified conditioning therapy with intravenous busulfan at 50% of the usual dose and fludarabine, before hematologic recovery occurred. Unmanipulated G-CSF mobilized peripheral blood stem cells from an HLA-identical sibling donor were transfused and haematopoietic recovery was achieved in both recipients. Both of them are in continuing hematological remission with full donor chimerism 12 and 22 months after transplantation. Early treatment intensification with allogeneic cell therapy during marrow aplasia might cure high-risk AML patients who are unlikely to achieve remission with conventional chemotherapy protocols.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313690     DOI: 10.1038/sj.bmt.1702819

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  1 in total

1.  Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.

Authors:  J Schetelig; M Schaich; K Schäfer-Eckart; M Hänel; W E Aulitzky; H Einsele; N Schmitz; W Rösler; M Stelljes; C D Baldus; A D Ho; A Neubauer; H Serve; J Mayer; W E Berdel; B Mohr; U Oelschlägel; S Parmentier; C Röllig; M Kramer; U Platzbecker; T Illmer; C Thiede; M Bornhäuser; G Ehninger
Journal:  Leukemia       Date:  2014-12-01       Impact factor: 11.528

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.